Information  X 
Enter a valid email address

PuriCore Plc (RLM)

  Print      Mail a friend       Annual reports

Friday 01 November, 2013

PuriCore Plc

Director/PDMR Shareholding

RNS Number : 9404R
PuriCore Plc
01 November 2013
 



1 November 2013

PuriCore plc

("PuriCore" or the "Company")

 

Director Dealing

 

 

PuriCore (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces a director dealing, in accordance with the Disclosure and Transparency Rules. On 31 October 2013, the following Director purchased shares in the Company, as set out below.

 

 

Name

Date purchased

Number of shares purchased

Purchase price of shares

Shareholding following the acquisition

% of issued share capital

Daniel Hegglin

Non-Executive Director

31 Oct 2013

 

1,000,000

 

45p

 

4,909,091

 

9.79%

 







 

Enquiries:

 

UK

US

FTI Consulting

Sage Strategic Marketing

Simon Conway/Mo Noonan

Jennifer Guinan

Victoria Foster Mitchell

+1 610.410.8111

+44 (0) 20 7831 3113

[email protected]

 

 

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients and staff in UK hospitals. PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and large animals in the animal health segment. In the Food & Agriculture market, PuriCore's portfolio is used by three of the top-five US supermarket retailers to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In addition, the Company is progressing its research and development programmes on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, US, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSWGGCGUUPWPWG

a d v e r t i s e m e n t